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Of the 63,000 people who died from drug overdose in 2016,
approximately 66% involved opioids,1 and 40% of opioid
overdoses were from prescription opioids.2 This demon-
strates the role of medical providers in the current opioid
epidemic. Each year in the United States, there are over 3
million vaginal deliveries and 1.3 million cesarean sections,
and up to 27and 75.5% of womenfilled an opioid prescription
after delivery at discharge for vaginal deliveries and cesarean
sections, respectively.2 As such, opioid prescribing for post-
delivery pain management is one of the most common
sources of prescribed opioids nationally.3,4 It is especially
relevant for the practicing obstetrician as 1 in 300 opioid
naïve patients becomes long-term opioid users.5 There are
no national guidelines for outpatient opioid prescribing,with
an optimal amount of post-delivery opioids not yet identified






Abstract Objective The aim of the study is to identify an association between inpatient opioid
consumption and prescription at discharge after vaginal delivery (VD) and cesarean
delivery (CD).
Methods This retrospective cohort study included women with an active inpatient
opioid order after VD or CD between July and October of 2018 at a single academic
tertiary hospital. Women with opioid use disorder, 3rd or 4th degree lacerations,
wound complications, and peripartum hysterectomy were excluded. Oxycodone 5-mg
(mg) tablets consumed postpartum and prescribed at discharge and sociodemo-
graphics were recorded. Primary outcome was the number of oxycodone 5-mg tablets
prescribed at discharge. Outcomes were analyzed using multivariable logistic regres-
sion between quartiles of inpatient opioid consumption.
Results A total of 437 patients were included: 169 patients underwent VD, and 268
underwent CD. For VD and CD, women in the highest quartile of inpatient opioid
consumption were more likely Black compared with the lowest quartile (p¼ 0.006 and
p¼ 0.004, respectively). No association existed between inpatient opioid use and
number of tablets prescribed at discharge for VD or CD (odds ratio [OR] 0.22 [95%
confidence interval or CI 0.02–2.17] and OR 1.04 [95% CI 0.85–1.32], respectively).
Conclusion The number of opioid tablets prescribed at discharge had no association
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Committee Opinion from ACOG (American College of Obste-
tricians and Gynecologists) recommends utilizing a multi-
modal stepwise approach to limit opioids administered
especially after cesarean delivery (CD).5 In other surgical
specialties, the Centers for Disease Control and Prevention
(CDC) recommends 3 days or less duration of treatment for
acute pain with an opioid, with a maximum duration of
7 days.6 Applying these recommendations to postpartum
patients would suggest that obstetric patients should expe-
rience the majority of their opioid consumption setting
inpatient after delivery,7 and that obstetricians overpre-
scribe opioids after cesarean section and vaginal delivery
(VD).3,4,8
One strategy to optimize post-delivery opioids prescrip-
tion is to tailor the number of opioid tablets prescribed
according to inpatient usage to ensure patient pain is appro-
priately treated without providing excess opioids. Indeed,
quantifying inpatient opioid consumption after vaginal and
CD could be helpful in guiding the amount of tablets for post-
discharge opioid prescribing. However, there is little data
evaluating inpatient opioid usage after VD and cesarean
sections in relation to the amount of opioids prescribed at
discharge. One prospective observational cohort studyof 179
women did suggest little association between inpatient
opioid usage and discharge prescribing amount after CD.9
Another retrospective study of 12,326 women highlighted
approximately 45.7% of women after VD who received an
opioid at time of discharge used 0-mg morphine equivalents
(MMEs) on final day of discharge.10 Our study adds to the
previous studies and more closely examines total inpatient
postpartum opioid consumption. This study aims to evaluate
whether there is an association between the amount of
tablets consumed during the entire inpatient postpartum
admission and the amount of tablets prescribed at hospital
discharge after both VD and cesarean section.
Materials and Methods
This retrospective cohort study included women who had an
active inpatient opioid order in the electronic medical record
(EMR) after a VD or cesarean section between July, 2018 and
October, 2018 at a single academic tertiary care center. The
datesselectedwere reflectiveof initiationofacentral electronic
medical record at our institution, allowing for identification of
eligible patients.Womenwere excluded if they had a history of
opioid usage prior to delivery, third- or fourth- degree lacera-
tion at time of delivery, wound complications, and peripartum
hysterectomy. Opioid usage prior to delivery was defined as a
known diagnosis of opioid use disorder or receipt ofmore than
one opioid prescription during pregnancy, as identified per
review of our comprehensive EMR, which integrates inpatient
and outpatient care at our institution. Wound complications
were defined as wound infections, seromas, or hematomas
requiring surgical or medical intervention. The Washington
University in St. Louis Human Research Protection Office
approved this study (IRB # 201901055).
The medical records of all women who delivered within
the study period were reviewed to identify eligible women.
Participant clinical and sociodemographic information was
extracted from qualifying subjects. Sociodemographic data
included age, race, body mass index (BMI), insurance payer,
length of post-delivery stay in days, and the discharge opioid
prescriber (intern, resident, or attending). Race was reported
as “Black” versus “White” as recorded in our EMR; the
minority of women who were neither Black nor White
were excluded given low prevalence at our institution.
The number of opioid tablets consumed post-delivery
while inpatient and prescribed at discharge were recorded.
At our institution, 5-mg oxycodone tablets are the most
prescribed inpatient opioid: 94.6 and 97.0% of prescriptions
are 5-mg oxycodone for VD and cesarean section, respective-
ly. Therefore, other forms of opioids were converted to MME
before being converted to 5-mg oxycodone tablets for ease of
comparison. The primary outcome of this study was the
number of oxycodone 5-mg tablets prescribed at discharge
after delivery, stratified by mode of delivery.
At our academic institution, our hospital obstetrical prac-
tice consists of both private and nonprivate patients. Routine
postpartum care universally involves nurse practitioners and
residents. It is routine to order oxycodone 5-mg tablets for
post-CD as needed for pain in postpartum order sets, while
not ordered for after VD. Inpatient postpartum opioids after
VD are ordered at physician discretion. Additionally, acet-
aminophen and ibuprofen are routinely ordered as sched-
uled after CD, and as needed after VD for first line pain
control. If any opioid is prescribed at discharge, both acet-
aminophen and ibuprofen are prescribed as first line agents,
and patients counseled on pain management. However,
there are no guidelines or recommendations for the amount
of opioid tablets prescribed at discharge after VD. For CD,
there are no formal guidelines or recommendations either,
but an arbitrary number is selected by the discharging
physician. A “common practice” of discharge is 5-mg oxyco-
done tablets after CD ranging from 10 to 30 tablets. Ulti-
mately, all discharge opioid prescriptions are at the
discretion of discharging physician. Discharge provider
includes either a resident physician, nurse practitioner, or
attending physician, with most commonly prescribing pro-
vider a nurse practitioner or resident physician.
Participants were stratified by mode of delivery into quar-
tiles by inpatient opioid usage. Demographic and baseline
clinical data were compared between women who had the
highest versus lowestquartile of inpatient opioidusageusing a
chi-square testor Fisher’s exact test for categoricalvariables, as
appropriate, and the Student’s t-test or Mann-Whitney U-test
for continuous variables. Multivariable regression models
stratifiedwomen by inpatient opioid use andmode ofdelivery
and analyzed primary outcomes, which were the number of
opioid tabletsprescribedatdischarge. ForwomenwhohadVD,
though there were differences in age, maternal BMI and race,
obstetric lacerations, and obstetric complications (such as
postpartum operating room procedure, hemorrhage, episiot-
omy, or cervical laceration) between the study groups, multi-
variable analyseswere not performeddue to small numbers in
the study population. Sensitivity analyses were then per-
formed excluding women who underwent bilateral tubal
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ligation (BTL) after VD. For womenwho had CD, multivariable
logistic regressionwasadjusted for race anddayofpostpartum
discharge. Sensitivity analyseswere thenperformedexcluding
womenwhowere discharged at or after postoperative dayfive
after CD.
Results
In total, 437 patients met inclusion criteria. Of these, 169
patients underwent VD, and 268 underwent CD.
Vaginal Delivery
Among the 169 included patients, the median number of
oxycodone 5-mg tablets consumed as an inpatient was one
tablet (interquartile range [IQR] 0, 3). However, 30.1%
(51/169) of patients received a prescription for oral opioids
on discharge. The median number of tablets prescribed at
discharge among patients who received a prescription was
15 (IQR 10, 20). Delivery, nearly one-third (n¼ 16; 32%)
received a postpartum opioid prescription, with a median
of 10 tablets (IQR 5, 16.25).
In ►Table 1, sociodemographic characteristics of the top
quartile of post-VD inpatient opioid users—who consumed
greater than or equal to three tablets (n¼ 58)—are compared
with the lowest quartile, who consumed 0 tablets (n¼ 50).
Highest quartile inpatient opioid usersweremore likely to be
Black (p¼ 0.006). The number of tablets consumed as an
inpatient were not related to mode of delivery (spontaneous
Table 1 Sociodemographics of patients who underwent vaginal delivery by quartile of inpatient opioid usage
Highest quartile
(three tablets or more)
(n¼ 58)
Lowest quartile (0 tablets)
(n¼ 50)
p-Value
Maternal age at delivery (median [SD]) years 29 (25, 32) 32.5 (26, 35) 0.03
Race/ethnicity (n [%])
White 17 (29.3) 13 (26.0) 0.006
Black 39 (67.2) 25 (50.0)
Other 2 (332.5) 12 (24.0)
Insurance type (n [%])
Private insurance 15 (25.9) 18 (36.0) 0.2
Public insurance 42 (72.4) 29 (58.0)
Other 1 (1.7) 3 (6.0)
Maternal BMI (median [IQR]) 31.6 (26.7, 36.2) 29.8 (24.8, 36.6) 0.6
Type of delivery (n [%])
Spontaneous 52 (89.7) 48 (96.0) 0.2
Vacuum assisted 3 (5.2) 2 (4.0)
Forceps assisted 3 (5.2) 0 (0.0)
Type of laceration (n [%]) (missing 1 from lowest quartile)
Intact 28 (48.3) 24 (49.0) 0.1
1st degree 3 (5.2) 8 (16.3)
2nd degree 12 (20.7) 13 (26.5)
3rd degree 1 (1.7) 1 (2.0)
4th degree 1 (1.7) 0 (0.0)
Other (periurethral, sulcal) 13 (22.4) 3 (6.1)
Complications (n [%])
None 43 (74.1) 40 (80.0) 0.08
BTL 14 (24.1) 5 (10.0)
Cervical laceration 0 (0.0) 2 (4.0)
Other (episiotomy, IUFD, DVT, trauma) 1 (1.7) 3 (6.0)
Discharge opioid subscribing provider (n [%])
Intern 23 (39.7) 15 (30.0) 0.2
Resident 23 (39.7) 28 (56.0)
Attending 12 (20.7) 7 (14.0)
Abbreviations: BTL, bilateral tubal ligation; DVT, deep venous thrombosis; IQR, interquartile range; IUFD, intrauterine fetal death; SD, standard
deviation.
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or operative VD), degree of perineal laceration, complica-
tions such as cervical laceration or BTL, or discharge pre-
scribing physician. As shown in ►Table 2, multivariate
analysis demonstrated no association between inpatient
opioid usage quartile and the number of tablets prescribed
at discharge. In a sensitivity analysis excluding patients who
underwent BTL, these findings were unchanged.
Cesarean Delivery
Of the 268 patients who had a CD, the median number of
oxycodone 5-mg tablets consumed during the inpatient
postoperative period was seven tablets (IQR 2.5, 12), and
94.7% (254/268) of women received an oral opioid prescrip-
tion at discharge. The median number of oxycodone 5-mg
tablets prescribed among those receiving a prescription at
discharge was 20 tablets (IQR 20, 21). Of the 14.6% (39/268)
patients who did not consume any opioid tablets in the
hospital after CD, 89.7% (35/39) received a narcotic prescrip-
tion at discharge, with a median of 20 oxycodone 5-mg
tablets (IQR 20, 20).
In ►Table 3, the sociodemographic characteristics of top
quartile of post-CD inpatient opioid users—who consumed
greater than or equal to 12 tablets (n¼ 74)—are compared
with the lowest quartile, who consumed less than 2.5 tablets
(n¼ 67). Highest quartile of inpatient opioid users were
more likely to be Black (p¼ 0.004). Patients who stayed until
postoperative day 4 were more likely to be in the highest
quartile of inpatient opioid users when compared with
womenwhowere discharged either on or after postoperative
day 5 or on less than postoperative day 3 (p¼ 0.02). There
was no association between inpatient opioid usage and type
of insurance or BMI. ►Table 4 presents analyses on our
primary outcome. There was no association between inpa-
tient opioid usage after CD and the number of tablets
prescribed at discharge, even after adjusting for race and
day of discharge. In a sensitivity analysis excluding patients
who were discharged after postoperative day 5, the findings
were unchanged.
Discussion
In this retrospective study, there was no correlation between
inpatient opioid consumption and the amount of opioids
prescribed at time of discharge after vaginal or CD. Further-
more, postpartum patients within our academic institution
received enough oral opioids to last up to 8 days after
delivery, exceeding the recommendation of 4 to 7 days of
acute pain treatment as per the CDC, regardless of inpatient
opioid consumption. Our results also suggest that imple-
mentation of standard prescribing after CD is potentially
leading to overprescribing; while subjective provider pre-
scribing after VD also leads to overprescribing lending to a
need for employing more applicable methodology at the
time of discharge.
The median amount of 5-mg oxycodone tablets pre-
scribedwas 15 and 20 among thosewho received a discharge
prescription after VD and CD, respectively. This is despite the
median inpatient opioid usage being 1 tablet (IQR 0–3) and 7
tablets (IQR 2.5–12) for vaginal and cesarean deliveries,
respectively. One potential explanation of such difference
between inpatient usage and opioids prescribed at discharge
is that providers may be accustomed to using a “one size fits
all” prescribing protocol after vaginal and cesarean deliver-
ies, which does not incorporate inpatient opioid use into
discharge prescribing protocols. This is perhaps best demon-
strated through those who had a VD and consumed no post-
delivery oral opioids receiving a median of 10 (IQR 5–16.25)
tablets at time of discharge. For cesarean sections, nonopioid
users in the postoperative setting had a median of 20 tablets
(IQR 20–21) prescribed at discharge, the same number for
Table 2 Multivariate regression of number of tablets prescribed at discharge by quartile of inpatient opioid usage after vaginal
delivery
# Oxycodone 5-mg tablets
prescribed at discharge (n [%])
Highest
quartile (n¼ 58)
Lowest quartile (0 tablets)
(n¼ 50)
Unadjusted OR
0 31 (53.5) 34 (68.0) 0.91 (0.56–1.48)
1–9 1 (1.7) 5 (10.0) 0.22 (0.02–1.98)
10–19 16 (27.6) 7 (14.0) 2.51 (0.91–6.90)
20–29 6 (10.3) 4 (8.0) 1.65 (0.42–6.38)
30 4 (6.9) 0 (0.0) –
Excluding women who underwent BTL
# Oxycodone 5-mg tablets prescribed
at discharge (n [%])
Highest quartile (n¼ 44) Lowest quartile (0 tablets)
(n¼ 45)
Unadjusted OR
0 27 (61.4) 33 (73.3) 0.82 (0.49–1.36)
1–9 1 (2.3) 3 (6.7) 0.41 (0.040–4.14)
10–19 9 (20.5) 5 (11.1) 2.20 (0.66–7.35)
20–29 4 (9.1) 4 (8.9) 1.22 (0.28–5.35)
30 3 (6.8) 0 (0.0) –
Abbreviations: BTL, bilateral tubal ligation; OR, odds ratio.
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routine postoperative oral opioid users. While the IQR after
CD suggests less of a variation of opioid prescribing, the
median number of tablets consumed as an inpatient is still
substantially less. Given it has been demonstrated that after
delivery approximately 3.86 million women each year are at
risk for continued opioid use, it is imperative to bridge the
gap between inpatient usage and opioid prescription at
discharge.4 One shared decision making study by Prabhu
et al suggested one approach to this dilemma, and imple-
mented shared decision making among 51 women after CD,
Table 3 Sociodemographics of patients who underwent cesarean delivery by quartile of inpatient opioid usage
Highest quartile (12 tablets)
(n¼ 74)
Lowest quartile (<2.5 tablets)
(n¼ 67)
p-Value
Maternal age at delivery (median [SD]) years 30 (26, 33) 30 (24, 35) 0.9
Race/Ethnicity (n [%])
White 25 (33.8) 40 (59.7) 0.004
Black 40 (54.1) 25 (37.3)
Other 9 (12.2) 2 (3.0)
Insurance type (n [%])
Private insurance 45 (60.8) 44 (65.7) 0.4
Public insurance 27 (36.5) 23 (34.3)
Other 2 (2.7) 0 (0.0)
Maternal BMI (median [IQR]) 33.8 (29.2, 39.8) 32.3 (26,6, 39.2) 0.3
Day of discharge (n [%])
PPD 3 or less 25 (33.8) 38 (56.7) 0.02
PPD 4 43 (58.1) 26 (38.8)
PPD 5 or more 6 (8.1) 3 (4.5)
Discharge opioid subscribing provider (n [%])
Intern 38 (51.4) 37 (55.2) 0.9
Resident 22 (29.7) 19 (28.4)
Attending 14 (18.9) 11 (16.4)
Abbreviations: IQR, interquartile range; PPD, PPD, postpartum day; SD, standard deviation.
Table 4 Multivariate regression of number of tablets prescribed at discharge by quartile of inpatient opioid usage after cesarean
delivery
# Oxycodone 5-mg tablets







Unadjusted OR Adjusted ORa
0 0 (0.0) 7 (10.5) – –
1–10 0 (0.0) 3 (4.5) – –
11–20 46 (62.2) 40 (59.7) 1.11 (0.77–1. 42) 1.04 (0.85–1.32)
21–30 26 (35.1) 16 (23.9) 1.41 (0.67–3.00) 1.68 (0.75–3.74)
31 2 (2.7) 1 (1.5) 1.74 (0.15–19.90) 1.85 (0.14–23.84)
Excluding DC after PPD 5
# Oxycodone 5-mg tablets






Unadjusted OR Adjusted ORb
0 0 (0.0) 7 (10.9) – –
1–10 0 (0.0) 3 (4.7) – –
11–20 42 (61.8) 38 (59.4) 1.10 (0.72–1.48) 1.05 (0.82–1.34)
21–30 25 (36.8) 15 (23.4) 1.51 (0.69–3.28) 1.64 (0.73–3.69)
31 1 (1.5) 1 (1.6) 0.91 (0.05–14.97) 0.69 (0.38–12.69)
Abbreviations: DC, discharge; OR, odds ratio; PPD, postpartum day.
aAdjusted for race and day of discharge.
bAdjusted for race.
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which showed 50% decrease in opioids prescribed postoper-
atively, but still demonstrated median 20 tablets prescribed
after cesarean section after shared decision making.11 This
suggests that additional implementation of review of inpa-
tient opioid usage at time of discharge couldmore accurately
depict opioid consumption to guide adequate discharge
opioid prescribing after vaginal and CD.9
Our finding that the number of tablets prescribed at
discharge was not associated with inpatient opioid usage
supports and adds to the current literature, which remains
limited inquantifying inpatientopioidusage afterdelivery. For
example, Badreldin et al found there was no association
betweenamountof tabletsprescribedatdischargeandmedian
MMEconsumed infinal24 hoursafterdelivery forbothvaginal
and cesareandeliveries.9Even further, theyalso identified that
nonopioid users could benefit most from utilizing inpatient
opioid consumption to direct postpartum discharge prescrip-
tions. This study appreciated 45.7 and 18.5% of nonopioid
using patients in the last 24 hours until discharge received an
opioid prescription after vaginal and CD, respectively.10 Our
retrospectivestudysupported thesefindingswithinadifferent
patient population: our study population was comprised
predominantly of Black women with a high proportion of
women with public insurance whereas the prior study was
comprised mostly of White women with private insurance.
Both studies suggestevaluating inpatient opioidusage as a tool
to tailor postpartum discharge prescribing after delivery.
This study had many strengths. First, our institution has a
centralized electronic medical record, which allowed us to not
only quantify number of tablets consumed during the entire
inpatient postpartum stay, but also exclude womenwho had a
prior history of opioid use disorder. Second, all data were
abstracted from the medical record by physicians, increasing
the accuracy of our findings. Third, we included all eligible
women during a prespecified time period, which limits the risk
of selectionbias. Additionally, despite theperiodofour included
patients starting in July at the time of matriculation of newer
intern physicians, the discharge prescribing physicians were
evenly distributed between intern, resident physician, and
attending physician. However, the study is not without limi-
tations. First, our study is retrospective in nature and was
conducted at a single institution, which may limit the
generalizability of our findings. Second, we were unable to
incorporate patient-reported pain scores during inpatient hos-
pitalization. Though these subjective pain measurements may
havedifferedbetween lowest andhighest inpatientopioidusers
—which could affect the amount of tablets prescribed at dis-
charge—they are inconsistently reported in the patient medical
record, particularly on or after postpartum day 2 or postopera-
tive day 3. Lastly, we were not able to perform multivariate
regression analysis forVDdue to smaller sample size,which can
limit identifying potential confounders.
In sum, our study demonstrated that the amount of opioids
prescribed at discharge had no associationwith the amount of
opioids consumed during inpatient postpartum stay despite
cofounders. Based on the CDC’s recommendation of acute pain
treatment, patients are likely to have themajority of the acute
pain episode while inpatient and therefore tailoring patient’s
discharge prescription based on inpatient usage can help
minimize overprescribing while providing adequate pain con-
trol. Additional prospective studies implementing prescribing
practices based on inpatient usage and pain scores along with
quantifying post discharge opioid usage arewarranted to help
eliminate overprescribing while maximizing adequate pain
control, andtohelpestablishnational standards inpostpartum
opioid prescribing.
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